Content about Endocrine system

DANBURY, Conn. — The Food and Drug Administration has given special designation to a treatment made by Biodel for patients with congenital hyperinsulinism, a rare disorder that affects children.

Biodel announced that it had received orphan drug designation for glucagon to prevent hypoglycemia, or abnormally low blood sugar, in patients with CHI.

DREXEL HILL, Pa. — The Community Specialty Pharmacy Network has entered a contract with Dara BioSciences to distribute a nonsteroidal anti-estrogen product.

CSPN announced the agreement with Dara to distribute Soltamox (tamoxifen) solution for oral administration. The drug, a treatment for breast cancer, is for patients who have difficulty swallowing pills.

BAGSVÆRD, Denmark — A Food and Drug Administration panel has voted to support two experimental insulin treatments made by Novo Nordisk, the Danish drug maker said Thursday.

Novo Nordisk said the FDA's Endocrinologic and Metabolic Drugs Advisory Committee had voted 8-to-4 in favor of approval for insulin degludec and a combination treatment containing insulin degludec and insulin aspart.

Natural Products Solutions recently announced the launch of VirMax T Testosterone. As part of that launch, DSN caught up with NPS president and CEO Marty Gallant to discuss men’s health supplements. 


DSN: Men aren’t too proactive addressing their own health issues. How do you market to them?


WOONSOCKET, R.I. — CVS/pharmacy has announced that it is partnering with the American Diabetes Association as the sponsor of "A Day in the Life of Diabetes" campaign — a photo-sharing campaign on the ADA's main Facebook page.

The CVS/pharmacy ExtraCare Advantage for Diabetes program will donate $1 to the American Diabetes Association for every photo or image uploaded, up to $25,000. CVS/pharmacy will also co-host a Twitter chat on Nov. 15 with Dr. Elizabeth Seaquist, VP medicine and science for the ADA.

MILPITAS, Calif. — Blood glucose monitoring is associated with reduced A1C levels and greater adherence to medication in Type 2 diabetes patients who do not take insulin, according to a study published in the September issue of Diabetes Technology & Therapeutics.

Beyond 2013, competitive bidding around durable medical equipment supplies could push many pharmacy operations out of the diabetes business altogether. “By 2016, all durable medical equipment suppliers, mail-order and retail, will be subject to competitive bidding or competitive bidding pricing for [diabetes testing supplies],” noted the NCPA in recent written testimony to Congress. According to an NCPA poll, that could drive as many as 92% of independents out of the 
diabetes business. 


The New York City health commissioner’s ban on the sale of big cups of fountain soda drew many an unfavorable accusation that the administration of mayor Michael Bloomberg was trying to turn the city into a nanny state, with NaturalNews.com editor Mike Adams asking, “What’s next? Is Bloomberg gonna pull a Singapore and ban chewing gum too?”


TIMONIUM, Md. — Natural Products Solutions recently announced the launch of VirMax T testosterone booster as the newest addition to the VirMax line of supplements. VirMax T made its official debut in early October at the 2012 National Association of Convenience Stores in Las Vegas and it currently is available in Circle K stores nationwide and on Walgreens' Drugstore.com site.

MILWAUKEE — Local programs in Wisconsin that help people living with diabetes are getting a big boost in funding from a Danish drug maker.

Novo Nordisk announced Wednesday that it would start accepting applications for Novo Nordisk Community Care Madison/Milwaukee, setting aside $100,000 for local programs that educate people with Type 2 diabetes. The partnerships are part of the company's Novo Nordisk Community Care program.

INDIANAPOLIS — Drug makers Boehringer Ingelheim and Eli Lilly have created a new online educational program for people with Type 2 diabetes.

The companies, which have had a deal to develop drugs for diabetes since January 2011 and co-market the drugs Tradjenta (linagliptin) and Jentadueto (linagliptin and metformin), announced Thursday the creation of My Well Planner, a lifestyle-improvement program for adults with the disease.

INDIANPOLIS — Lilly Diabetes announced that it has launched a new mobile application designed for caregivers and healthcare providers who support people with Type 1 diabetes.

The Lilly Glucagon mobile app is an interactive tool designed to teach caregivers how to use severe hypoglycemia treatment Glucagon (1-mg) for injection through simulated practice, thus helping caregivers better understand Glucagon's role in diabetes management. The Lilly Glucagon mobile app includes:

• Information about severe hypoglycemia and Glucagon;